bispecific antibodies to recruit T cells and separately engineered CAR-NK cells both of which can mediate cell-based killing of the Siglec-8 positive cells. For the bispecific antibodies and CAR-NK ...

and monoclonal antibodies, a definitive cure remains elusive, highlighting an urgent need for novel therapeutic strategies. Recent studies indicate that chimeric antigen receptor T-cell (CAR-T) ...

Scripps Research Institute spin-out Calibr's lead candidate combines CLBR001 cells – billed as a "universal" CAR-T because they are not targeted at a specific antigen – and companion antibody ...

a protein on the surface of B-cells that is also targeted by Amgen’s bispecific antibody Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL), as well as two CAR-T therapies ...

Well, in this situation, it is all about B cells, a type of white blood cell that makes infection-fighting proteins called antibodies. CAR-T researchers are currently very focused on a group of ...

Despite its inception over 100 years ago, immunotherapy (IT) only began to gain serious traction in the 1980s with the advent of monoclonal antibodies (mAbs ... to the emerging field of CAR-T ...

1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany. *Corresponding Author: Maximilian Merz, Department of Hematology, Hemostaseology and ...

Physician-researchers with City of Hope have developed a way to add features to T cells to help them overcome mechanisms of ...